Jubilant Life Sciences on Tuesday reported a more than 22 per cent jump in its net profit for the quarter-ended June 30, 2016, at ₹161.6 crore. The company had registered profit of ₹131.93 crore during the corresponding quarter of the previous fiscal.
The company’s income, however, saw a small dip during the quarter at ₹1,419.53 crore against ₹1,445.7 crore during the June quarter last year.
In a joint statement, Shyam S Bhartia, Chairman, and Hari S Bhartia, Co-Chairman and Managing Director, Jubilant Life Sciences, said: “We have started the fiscal year 2017 on a positive note delivering strong performance in the pharmaceuticals segment, which contributed about 70 per cent of the company’s operating profit… Our company has built a robust long-term sustainable business model with the growth engine of pharmaceuticals and drug discovery solutions segments.”
The company has posted a 7 per cent increase in revenues from the pharmaceutical segment at ₹752 crore, 67 per cent of which came from North America.
Jubilant Life Science’s scrip closed at ₹341.9, higher by 3.61 per cent.